Endocrine Abstracts

Background: Patients with acromegaly have substantially reduced quality of life (QoL). Delayed diagnosis is common and a long duration of untreated acromegaly leads to decreased QoL and increased morbidity and mortality.

Aim: This longitudinal study examined QoL in patients with acromegaly who received lanreotide autogel.

Material and Methods: This was a 2-year prospective, observational, multicenter study conducted in Poland (NCT02396966). We included patients with acromegaly who received treatment with lanreotide autogel 120 mg for ≥ 3 months and <3 years. QoL was measured with the Acromegaly Quality of Life questionnaire (AcroQoL).

Results: Of 152 patients enrolled from November 2014 to May 2018 in 37 centers, 24 were excluded due to major protocol deviations; thus, results are reported for 128 patients in the study population. At baseline, the median (95% CI) time from diagnosis was 3.3 (2.8, 4.2) years, and the median (95% CI) time since lanreotide autogel initiation was 13.4 (10; 17) months. In 85.9% patients, acromegaly was symptomatic at baseline; headaches (57.0%), sweating (57.8%), and joint symptoms (64.1%) were most common. Hormonal and symptomatic control was stable from baseline to study completion. At baseline, treatment satisfaction was high (88.3% completely or rather satisfied). During the study, treatment satisfaction was unchanged for 88.2% of patients. Mean (95% CI) AcroQoL scores at baseline were as follows: total score, 50.3 (47.3, 53.3); physical dimension, 48.8 (45.2, 52.4); psychological dimension, 51.3 (48.2, 54.4); appearance subdimension, 40.7 (37.5, 43.8); and personal relations subdimension, 62.5 (58.8, 66.2). From baseline to month 24, the appearance subdimension improved 3.8 points (1.1, 6.4), whereas the remaining AcroQoL scores did not change substantially. The total AcroQoL score remained unchanged over 2 years regardless of prior acromegaly treatment, prior surgery, prior radiotherapy, biochemical control, or lanreotide dosing interval. No new safety findings were identified.

Conclusions: Overall, global QoL and its physical and psychological aspects remained stable albeit compromised despite hormonal and symptomatic control throughout the study, whereas the AcroQoL psychological appearance subdimension improved. Most subjects remained satisfied with treatment during the study.

Keywords: acromegaly, somatostatin analogue, lanreotide, quality of life, AcroQoL